The Commonwealth of Kentucky Attorney General’s office announced a $15.5 million dollar settlement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, over allegations that Janssen misled Kentucky consumers about its drug Risperdal and marketed the drug for purposes other than that approved by the FDA.
“Janssen and Johnson & Johnson put patients at risk when they marketed Risperdal without disclosing the drug’s known side effects,” Attorney General Jack Conway said in the December 23, 2015 announcement. “These side effects were even more harmful to children and elderly patients.”
Bailey Cowan Heckaman PLLC represented Kentucky as lead outside counsel in the case. Including this settlement, BCH has amassed over $159 million in consumer protection judgments and settlements against Janssen over the marketing and promotion of its antipsychotic drug Risperdal. In the Kentucky case, Tad Thomas of the Thomas Law Offices served as BCH’s co-counsel.
Attorney General Conway’s press release concerning the Kentucky Risperdal settlement is available here.